| Peter George Pantelidis, MD | |
|
799 Farson St Ste 210, Belpre, OH 45714-1044 | |
| (740) 423-3082 | |
| (740) 423-3083 |
| Full Name | Peter George Pantelidis |
|---|---|
| Gender | Male |
| Speciality | Pain Management |
| Experience | 24 Years |
| Location | 799 Farson St Ste 210, Belpre, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1770570186 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Marietta Memorial Hospital | Marietta, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Marietta Memorial Hospital | 8224928965 | 326 |
| Marietta Memorial Hospital Of Tyler County Inc | 4385055342 | 11 |
News Archive
MicroStockProfit.com announces an investment report featuring Catalyst Pharmaceutical Partners Inc.. The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.
Cardiac resynchronization therapy with defibrillators (CRT-D) is appropriate for patients who have left ventricular dysfunction and require chronic ventricular pacing, based on the findings of an observational study that being presented March 26 that the 61st annual American College of Cardiology (ACC) scientific session.
Obesity has been linked to "letter" changes at many different sites in the genome, yet these differences do not fully explain the variation in people's body mass index (BMI) or why some overweight people develop health complications while others don't.
3D-printed, disposable sensors capable of detecting noxious gases and changes in temperature and humidity, could revolutionize environmental monitoring.
Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patients with active cancer. The studies are evaluating the medicine for the prevention and treatment of life-threatening blood clots in patients with a wide range of cancer types.
› Verified 4 days ago
| Entity Name | Marietta Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215936927 PECOS PAC ID: 8224928965 Enrollment ID: O20040317000973 |
News Archive
MicroStockProfit.com announces an investment report featuring Catalyst Pharmaceutical Partners Inc.. The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.
Cardiac resynchronization therapy with defibrillators (CRT-D) is appropriate for patients who have left ventricular dysfunction and require chronic ventricular pacing, based on the findings of an observational study that being presented March 26 that the 61st annual American College of Cardiology (ACC) scientific session.
Obesity has been linked to "letter" changes at many different sites in the genome, yet these differences do not fully explain the variation in people's body mass index (BMI) or why some overweight people develop health complications while others don't.
3D-printed, disposable sensors capable of detecting noxious gases and changes in temperature and humidity, could revolutionize environmental monitoring.
Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patients with active cancer. The studies are evaluating the medicine for the prevention and treatment of life-threatening blood clots in patients with a wide range of cancer types.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Peter George Pantelidis, MD Po Box 449, Marietta, OH 45750-0449 Ph: () - | Peter George Pantelidis, MD 799 Farson St Ste 210, Belpre, OH 45714-1044 Ph: (740) 423-3082 |
News Archive
MicroStockProfit.com announces an investment report featuring Catalyst Pharmaceutical Partners Inc.. The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.
Cardiac resynchronization therapy with defibrillators (CRT-D) is appropriate for patients who have left ventricular dysfunction and require chronic ventricular pacing, based on the findings of an observational study that being presented March 26 that the 61st annual American College of Cardiology (ACC) scientific session.
Obesity has been linked to "letter" changes at many different sites in the genome, yet these differences do not fully explain the variation in people's body mass index (BMI) or why some overweight people develop health complications while others don't.
3D-printed, disposable sensors capable of detecting noxious gases and changes in temperature and humidity, could revolutionize environmental monitoring.
Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patients with active cancer. The studies are evaluating the medicine for the prevention and treatment of life-threatening blood clots in patients with a wide range of cancer types.
› Verified 4 days ago